Evaluation of Phage Display Biopanning Strategies for the Selection of Anti-Cell Surface Receptor Antibodies.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Jul 2022
Historique:
received: 30 06 2022
revised: 28 07 2022
accepted: 28 07 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 16 8 2022
Statut: epublish

Résumé

Monoclonal antibodies (mAbs) are one of the most successful and versatile protein-based pharmaceutical products used to treat multiple pathological conditions. The remarkable specificity of mAbs and their affinity for biological targets has led to the implementation of mAbs in the therapeutic regime of oncogenic, chronic inflammatory, cardiovascular, and infectious diseases. Thus, the discovery of novel mAbs with defined functional activities is of crucial importance to expand our ability to address current and future clinical challenges. In vitro, antigen-driven affinity selection employing phage display biopanning is a commonly used technique to isolate mAbs. The success of biopanning is dependent on the quality and the presentation format of the antigen, which is critical when isolating mAbs against membrane protein targets. Here, we provide a comprehensive investigation of two established panning strategies, surface-tethering of a recombinant extracellular domain and cell-based biopanning, to examine the impact of antigen presentation on selection outcomes with regards to the isolation of positive mAbs with functional potential against a proof-of-concept type I cell surface receptor. Based on the higher sequence diversity of the resulting antibody repertoire, presentation of a type I membrane protein in soluble form was more advantageous over presentation in cell-based format. Our results will contribute to inform and guide future antibody discovery campaigns against cell surface proteins.

Identifiants

pubmed: 35955604
pii: ijms23158470
doi: 10.3390/ijms23158470
pmc: PMC9369378
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Membrane Proteins 0
Peptide Library 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Australian Research Council
ID : IC16100027

Références

J Immunol. 1999 Feb 15;162(4):2129-36
pubmed: 9973487
J Immunol. 2008 Jan 15;180(2):1199-206
pubmed: 18178860
MAbs. 2016;8(3):436-53
pubmed: 26651396
Biophys J. 2000 Jan;78(1):394-404
pubmed: 10620303
Anal Biochem. 2010 Jan 1;396(1):59-68
pubmed: 19720041
Blood. 2008 Apr 1;111(7):3830-7
pubmed: 18230757
Sci Rep. 2016 May 18;6:26240
pubmed: 27189586
MAbs. 2016 Oct;8(7):1177-1194
pubmed: 27416017
Biotechniques. 1999 Feb;26(2):208-10, 214
pubmed: 10023526
J Immunol Methods. 1992 Nov 5;155(2):241-8
pubmed: 1431152
Biotechnol Prog. 2009 Jan-Feb;25(1):244-51
pubmed: 19224598
J Cell Physiol. 2019 Jun;234(6):9486-9494
pubmed: 30417355
Nature. 1990 Dec 6;348(6301):552-4
pubmed: 2247164
Protein Expr Purif. 2020 Mar;167:105524
pubmed: 31678667
Mol Cell Proteomics. 2016 Jul;15(7):2435-47
pubmed: 27094473
J Gen Physiol. 2016 Apr;147(4):353-68
pubmed: 26976827
Curr Opin Struct Biol. 2008 Oct;18(5):581-6
pubmed: 18674618
Front Immunol. 2020 Aug 28;11:1986
pubmed: 32983137
Anal Biochem. 2013 Oct 15;441(2):208-13
pubmed: 23906643
J Biosci Bioeng. 2001;91(5):474-81
pubmed: 16233025
J Biotechnol. 2012 Oct 31;161(3):336-48
pubmed: 22814405
Nat Protoc. 2014 Jul;9(7):1578-91
pubmed: 24901741
MAbs. 2019 Feb/Mar;11(2):350-372
pubmed: 30466347
Biotechnol Bioeng. 2020 Jan;117(1):5-16
pubmed: 31631329
J Pharm Sci. 2014 Jun;103(6):1613-1627
pubmed: 24740840
Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201
pubmed: 23535386
ACS Sens. 2021 Mar 26;6(3):764-776
pubmed: 33481587
Biotechnol Prog. 2019 Nov;35(6):e2884
pubmed: 31301216
J Allergy Clin Immunol. 2003 Oct;112(4):653-65; quiz 666
pubmed: 14564341
Antibodies (Basel). 2017 Aug 05;6(3):
pubmed: 31548525
MAbs. 2014 Jan-Feb;6(1):204-18
pubmed: 24262918
PLoS One. 2013 Sep 09;8(9):e72272
pubmed: 24039747
Cell. 2008 Aug 8;134(3):496-507
pubmed: 18692472
Biochemistry. 2020 Nov 10;59(44):4285-4293
pubmed: 33118810
J Microbiol Immunol Infect. 2017 Apr;50(2):160-166
pubmed: 26066544
J Biol Chem. 2019 Sep 6;294(36):13434-13444
pubmed: 31337703
Commun Biol. 2018 Apr 5;1:23
pubmed: 30271910
J Biotechnol. 2019 Jan 10;289:88-92
pubmed: 30496775
J Immunol Methods. 2010 Mar 31;354(1-2):85-90
pubmed: 20153332
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
Mol Biotechnol. 2019 Apr;61(4):286-303
pubmed: 30729435
Biotechnol Bioeng. 2009 Jun 15;103(3):542-51
pubmed: 19199356
Front Immunol. 2020 Feb 18;11:241
pubmed: 32133009
J Immunol. 2004 May 1;172(9):5489-94
pubmed: 15100290
Front Immunol. 2017 May 31;8:608
pubmed: 28620376
Cytotechnology. 2019 Feb;71(1):305-316
pubmed: 30637508
Front Pharmacol. 2019 Jul 30;10:847
pubmed: 31417405

Auteurs

Nadya Panagides (N)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

Lucia F Zacchi (LF)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

Mitchell J De Souza (MJ)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Rodrigo A V Morales (RAV)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Alexander Karnowski (A)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Mark T Liddament (MT)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Catherine M Owczarek (CM)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Stephen M Mahler (SM)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

Con Panousis (C)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, VIC 3052, Australia.

Martina L Jones (ML)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

Christian Fercher (C)

ARC Training Centre for Biopharmaceutical Innovation, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4072, Australia.

Articles similaires

Genome, Viral Ralstonia Composting Solanum lycopersicum Bacteriophages
Humans Stomach Neoplasms Macrophages Tumor Microenvironment Disease Progression
Host Specificity Bacteriophages Genomics Algorithms Escherichia coli
Animals Humans TOR Serine-Threonine Kinases Lupus Erythematosus, Systemic Arthritis, Rheumatoid

Classifications MeSH